Citalopram in the treatment of elderly chronic heart failure combined with depression: A systematic review and meta-analysis

Longmei Yan, Yuzhen Ai, Yaxuan Xing, Biqing Wang, Anran Gao, Qiwu Xu, Wanqing Li, Keji Chen, Jingchun ZhangFrontiers in Cardiovascular Medicine 2023 · DOI

TL;DR

This systematic review and meta-analysis finds that the antidepressant citalopram not only alleviates depressive symptoms in elderly patients with chronic heart failure (HF) but also provides measurable improvements in cardiac function, specifically increasing Left Ventricular Ejection Fraction (LVEF) and reducing NT-proBNP levels. Importantly, the treatment appeared safe for this high-risk population, showing no significant increase in adverse drug reactions compared to control groups.

What Problem Does This Paper Address?

Heart failure and depression often form a "vicious cycle." Depression is an independent predictor of hospitalization and mortality in HF patients, with a prevalence significantly higher than in the general population (ranging from 31% to 77.5%). While major cardiology guidelines (ESC and ACC/AHA) recommend screening for and treating depression, they are notably deficient in specific pharmacological recommendations.

The effectiveness of antidepressant therapy on actual cardiac outcomes remains controversial. Some clinicians worry about the cardiovascular side effects of antidepressants—such as QTc prolongation—especially in elderly patients with existing heart disease. This paper seeks to clarify whether citalopram, a common Selective Serotonin Reuptake Inhibitor (SSRI), is both safe and effective for this specific "comorbid" population.

Methods

The authors conducted a systematic review and meta-analysis following the PRISMA statement. They searched eight major databases (including PubMed, Cochrane, and CNKI) for randomized controlled trials (RCTs) published up to May 2022.

Key methodological features included:

  • Inclusion Criteria: RCTs involving adults aged 60+ diagnosed with both chronic HF and depression.
  • Intervention: Citalopram (or its isomer escitalopram) vs. conventional treatment or placebo.
  • Quality Assessment: The Cochrane risk-of-bias tool was used to evaluate the internal validity of the included studies.
  • Statistical Analysis: Data were synthesized using Review Manager 5.4.1, employing random-effect or fixed-effect models based on the level of heterogeneity ($I^2$).

Datasets

The study synthesized data from 8 randomized controlled trials involving a total of 1,141 patients (573 in experimental groups, 568 in control groups). The trials were conducted between 2011 and 2020. While the search included international databases, a significant portion of the included literature originated from Chinese clinical trials.

Key Insights and Ideas

  • The Heart-Mind Connection: The most striking insight is that treating a psychological condition (depression) yielded physiological improvements in the heart. The reduction in NT-proBNP (a biomarker of heart stress) suggests that alleviating depression may reduce the "sympathetic storm" or inflammatory load on the cardiovascular system.
  • Selective Efficacy Across Scales: Interestingly, citalopram showed significant benefits on the HAMD-24 and GDS (Geriatric Depression Scale) but did not show a statistically significant difference on the HAMD-17 or MADRS. This suggests that certain depression scales may be more sensitive to the specific symptom clusters found in elderly HF patients.
  • Safety Profile: Despite concerns about SSRIs and heart rhythms, this meta-analysis found that citalopram did not increase the incidence of adverse reactions like nausea, dizziness, or fatigue compared to controls, supporting its use as a relatively safe option for elderly HF patients.
  • Heterogeneity in Cardiac Remodeling: While LVEF (pumping efficiency) improved, LVEDD (heart chamber size) did not show significant change. This suggests that citalopram might improve the function of existing heart muscle more readily than it reverses structural remodeling.

Key Results

  • Cardiac Function:
    • LVEF: Significant improvement (Mean Difference [MD]: 2.42%, 95% CI: 0.51 to 4.33).
  • NT-proBNP: Significant reduction (MD: −537.78 pg/mL, 95% CI: −718.03 to −357.54).
  • LVEDD: No significant difference (MD: −1.45 mm).
  • Depression Scores:
    • HAMD-24: Significant improvement (MD: −8.51, 95% CI: −10.15 to −6.88).
  • GDS: Significant improvement noted in individual studies.
  • HAMD-17 & MADRS: No statistically significant difference compared to controls.
  • Safety: The Odds Ratio (OR) for adverse reactions was 0.88 (95% CI: 0.65 to 1.20, p=0.43), indicating no significant increase in risk.

Limitations and Future Work

The authors acknowledge several limitations that temper these findings:

  1. Small Study Count: Only 8 trials met the inclusion criteria, and some had small sample sizes.
  2. Methodological Transparency: Many included trials failed to provide details on "allocation concealment," which is a key metric for preventing selection bias.
  3. Language and Geography: A large number of the studies were published in Chinese, potentially limiting the generalizability of the results to other global populations.
  4. Chemical Variation: The meta-analysis grouped citalopram and escitalopram together; while chemically related, they have different potencies that might affect results.

Future Work: The authors call for large-scale, multicenter, double-blind, international RCTs to confirm these benefits and to determine the optimal dosage and duration of treatment for this vulnerable patient group.

Summary updated

Abstract

Citalopram treatment for depressed patients with chronic HF has a positive effect on LVEF and NT-proBNP. It can alleviate HAMD-24 and GDS, but the relative benefits for LVEDD, HAMD-17 and MADRS still need to be verified.<b>Systematic Review Registration</b>: PROSPERO [CRD42021289917].
BibTeX
@inproceedings{yan2023citalopram,
  author = {Longmei Yan and Yuzhen Ai and Yaxuan Xing and Biqing Wang and Anran Gao and Qiwu Xu and Wanqing Li and Keji Chen and Jingchun Zhang},
  title = {{Citalopram in the treatment of elderly chronic heart failure combined with depression: A systematic review and meta-analysis}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2023},
  doi = {10.3389/fcvm.2023.1107672},
}
Figure